Please activate JavaScript!
Please install Adobe Flash Player, click here for download

Labbook 2015

Chemistry&Immunochemistry LABBOOK 2015 13 Highlights: •• An open system, random access chemistry analyzer •• Original "Air pressure mixing system" avoids carry-over •• More than 5,500 units are sold in 73 countries •• Water consumption is only 3.5 L /hour at the maximum •• Individual probes are used for R1 and R2 95 kgWeight: 520 x 800 x 670 mm (h x w x d)Dimensions: 600 WPower consumption: 240 tests/h without ISE, 400 tests/hour with ISE Sample throughput: Tokyo Boeki Machinery Ð BIOLIS24i Premium 300 kgWeight: 1145 x 1050 x 750 mm (h x w x d)Dimensions: 1200 WPower consumption: 480 tests/h without ISE, 580 tests/h with ISE Sample throughput: Highlights: •• An open system, random access chemistry analyzer •• Hemolysis of whole blood sample for HbA1c is available automatically •• Clot detector for the sample enhances the accuracy of the test results •• Less water and power consumption (13L/hour, 1.2KVA) Tokyo Boeki Machinery Ð BIOLIS50i Superior IMMUNOCHEMISTRY Highlights: >50 preprogrammed, bar-coded immunoassay methods Assays: Up to 400 tests/hSample throughput: 630 kgWeight: 1700 x 1710 x 970 mm (h x w x d)Dimensions: The UniCel DxI 800 has exceptional throughput, proven chemiluminescent technology and assay proto- cols similar to other analyzers in the Beckman Coulter family Ð so you can simplify and automate your immunoassay testing. The UniCel DxI 800 immuno- assay system allows laboratories to decrease process steps and improve turnaround time Ð with ease of use. Beckman Coulter Ð UniCel DxI 800 Access Immunoassay System Highlights: The Access AccuTnI+3 troponin I assay delivers the precision, clinical sensitivity and clinical specificity necessary to assist physicians with the diagnosis of myocardial infarction (MI). Access AccuTnI+3 troponin I in the core lab gets physicians the critical results they need and can cut triage time in half. The assay can use two serial samples collected within a 3-hour period, rather than waiting for a six-hour period, to provide a more accurate diagnoses. A large multicenter prospec- tive clinical trial on the AccuTnI+3 assay confirmed that the assay provides the clinical performance needed for proper patient management. Beckman Coulter Ð Access AccuTnI+3 Troponin I Assay LABBOOK 201513

Seitenübersicht